Antiretroviral therapy coverage for PMTCT in Burundi

Burundi: Antiretroviral therapy coverage for PMTCT was 65.0% in 2024. ◆ Volatile

Latest (2024)
65.0%
Change on year
down 4.4%
World rank
58th
of 84 countries
All-time high
100.0%
in 2016
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Antiretroviral therapy coverage for PMTCT in Burundi, 2000–2024

0204060801002000201220242000: 0 % of pregnant women living with HIV2001: 0 % of pregnant women living with HIV2002: 2 % of pregnant women living with HIV2003: 4 % of pregnant women living with HIV2004: 8 % of pregnant women living with HIV2005: 18 % of pregnant women living with HIV2006: 22 % of pregnant women living with HIV2007: 22 % of pregnant women living with HIV2008: 31 % of pregnant women living with HIV2009: 34 % of pregnant women living with HIV2010: 57 % of pregnant women living with HIV2011: 60 % of pregnant women living with HIV2012: 64 % of pregnant women living with HIV2013: 74 % of pregnant women living with HIV2014: 86 % of pregnant women living with HIV2015: 98 % of pregnant women living with HIV2016: 100 % of pregnant women living with HIV2017: 100 % of pregnant women living with HIV2018: 100 % of pregnant women living with HIV2019: 100 % of pregnant women living with HIV2020: 95 % of pregnant women living with HIV2021: 77 % of pregnant women living with HIV2022: 77 % of pregnant women living with HIV2023: 68 % of pregnant women living with HIV2024: 65 % of pregnant women living with HIV

Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.

Analysis

The most recent figure for antiretroviral therapy coverage for pmtct in Burundi is 65.0%, measured in 2024.

The figure is down 4.4% on the previous year and down 24.4% over ten years.

Over the whole period, antiretroviral therapy coverage for pmtct in Burundi peaked at 100.0% in 2016 and was at its lowest, 0.0%, in 2000.

Burundi ranks 58th of 84 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Antiretroviral therapy coverage for PMTCT in Burundi, year by year

Annual values for Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) in Burundi, 2000 to 2024.
Year % of pregnant women living with HIV Change
2000 0.0%
2001 0.0%
2002 2.0%
2003 4.0% +100.0%
2004 8.0% +100.0%
2005 18.0% +125.0%
2006 22.0% +22.2%
2007 22.0% +0.0%
2008 31.0% +40.9%
2009 34.0% +9.7%
2010 57.0% +67.6%
2011 60.0% +5.3%
2012 64.0% +6.7%
2013 74.0% +15.6%
2014 86.0% +16.2%
2015 98.0% +14.0%
2016 100.0% +2.0%
2017 100.0% +0.0%
2018 100.0% +0.0%
2019 100.0% +0.0%
2020 95.0% -5.0%
2021 77.0% -18.9%
2022 77.0% +0.0%
2023 68.0% -11.7%
2024 65.0% -4.4%

Burundi compared with similar countries

  • Burundi's 65.0% is below the median for low income countries, which is 73.0%, 89% of the median. (22 countries reporting)
  • Burundi's 65.0% is below the median for Sub-Saharan Africa, which is 82.0%, 79% of the median. (41 countries reporting)

Biggest year-on-year movements

Years where Antiretroviral therapy coverage for PMTCT in Burundi changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2005 +125.0% 8.0% 18.0%
2003 +100.0% 2.0% 4.0%
2004 +100.0% 4.0% 8.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 14.1% 0.0% 34.0% 10
2010s 83.9% 57.0% 100.0% 10
2020s 76.4% 65.0% 95.0% 5

Countries ranked near Burundi

  1. 56 El Salvador 66.0% compare
  2. 56 Suriname 66.0% compare
  3. 58 Nepal 65.0% compare
  4. 60 Niger 63.0% compare
  5. 61 Haiti 60.0% compare

See the full ranking of 99 places →

More health data for Burundi

All data for Burundi →

Frequently asked questions

What is antiretroviral therapy coverage for pmtct in Burundi?
Antiretroviral therapy coverage for pmtct in Burundi was 65.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
What is the highest antiretroviral therapy coverage for pmtct recorded in Burundi?
The highest recorded value was 100.0% in 2016.
What is the lowest antiretroviral therapy coverage for pmtct recorded in Burundi?
The lowest recorded value was 0.0% in 2000.
How does Burundi rank for antiretroviral therapy coverage for pmtct?
Burundi ranks 58th out of 84 countries with data for 2024.
Is antiretroviral therapy coverage for pmtct rising or falling in Burundi?
Over the last ten years it is down 24.4%. The long-run trend across the full record is volatile.
Where does this Burundi data come from?
The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Antiretroviral therapy coverage for PMTCT in Burundi. Statizoid, drawing on UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved 18 September 2026, from https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/burundi/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/burundi/">Antiretroviral therapy coverage for PMTCT in Burundi</a> — Statizoid

About this data

Indicator
Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Unit
% of pregnant women living with HIV
Source
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
99 places, 2,393 data points, 2000–2024
Last refreshed

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).